GENMAB A/S |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 25.8 EUR | -.--% |
|
-4.44% | -10.42% |
| 05-21 | Genmab A/S Reaffirms Financial Guidance for 2024 | CI |
| 05-21 | Genmab A/S completed the acquisition of ProfoundBio, Inc. | CI |
| Sales 2024 * | 19.8B 2.88B 2.65B 3.92B | Sales 2025 * | 23.62B 3.43B 3.16B 4.68B | Capitalization | 125B 18.17B 16.73B 24.74B |
|---|---|---|---|---|---|
| Net income 2024 * | 4.67B 679M 626M 925M | Net income 2025 * | 6.61B 962M 886M 1.31B | EV / Sales 2024 * | 5 x |
| Net cash position 2024 * | 25.9B 3.77B 3.47B 5.13B | Net cash position 2025 * | 32.35B 4.7B 4.33B 6.41B | EV / Sales 2025 * | 3.92 x |
| P/E ratio 2024 * |
28.5
x | P/E ratio 2025 * |
20.5
x | Employees | - |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.51% |
More Fundamentals
* Assessed data
More news
Latest transcript on Genmab A/S
More recommendations
More press releases
More news
| 1 week | -4.44% | ||
| Current month | -3.01% | ||
| 1 month | -3.01% | ||
| 3 months | +1.57% | ||
| 6 months | -9.15% | ||
| Current year | -10.42% |
1 week
25.80
26.20
1 month
25.8027.60
3 years
24.6044.40
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 63 | 98-12-31 | |
Anthony Pagano
DFI | Director of Finance/CFO | 46 | 06-12-31 |
Anthony Mancini
COO | Chief Operating Officer | 53 | 20-03-22 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Deirdre Connelly
CHM | Chairman | 63 | 16-12-31 |
| Director/Board Member | 73 | 03-10-31 | |
Rolf K. Hoffmann
BRD | Director/Board Member | 64 | 15-12-31 |
| Date | Price | Change |
|---|---|---|
| 24-05-31 | 25.8 | -.--% |
| 24-05-30 | 25.8 | -.--% |
| 24-05-29 | 25.8 | -1.53% |
| 24-05-28 | 26.2 | +1.55% |
| 24-05-27 | 25.8 | -4.44% |
Delayed Quote Deutsche Boerse AG, May 31, 2024 at 02:03 am
More quotes
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows:
- royalties (83.2%);
- income from research and development (12.4%);
- other (4.4%): primarily income from partnership agreement.
At the end of 2023, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase.
Denmark accounts for all net sales.
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
23
Last Close Price
1,937
DKK
Average target price
2,466
DKK
Spread / Average Target
+27.30%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +11.91% | 118B | |
| +11.60% | 106B | |
| -4.68% | 24.28B | |
| -0.82% | 21.96B | |
| -42.12% | 16.37B | |
| -17.47% | 15.56B | |
| +2.77% | 13.63B | |
| +34.58% | 12.27B | |
| +77.64% | 8.87B |
- Stock Market
- Equities
- GMAB Stock
- GE91 Stock
